Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Clinical laboratories / Routine core-lab testing

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Routine core-lab testing

Hospital and reference laboratories buying reagents, consumables and automated analysers for high-volume routine in-vitro tests such as haematology, clinical chemistry, immunoassays and urinalysis, where the job is to process daily sample volumes with reliable, standardised results at controlled cost per test.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
80 /100
for B2B sellers
Evidence
not sized
5 sources · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Hospital and reference laboratories
Buying centre
Laboratory director or chief pathologist (technical and budget owner), procurement (commercial terms), and platform/instrument evaluation committee (analyser selection)
Buying triggers
  • Rising test volumes from ageing populations and chronic disease management
  • Replacement or expansion of routine analyser fleets
  • Tender renewal or contract re-bidding
  • Pressure to reduce cost per reportable test and standardise across sites
Pains
  • Fragmented supplier portfolios and inconsistent assay performance across analysers
  • Reagent wastage, instability and cold-chain handling costs
  • Instrument utilisation below target levels
  • Budget scrutiny and procurement pressure on unit economics
Scores (1–5)
Pain intensity4
Purchasing power4
Reachability5
Growth3

How this was sized

Not sized yet

No source in the provided set isolates the routine core-lab product segment (reagents, consumables and analysers) from specialised or molecular testing, so no defensible revenue-pool figure is given. Source [8] reports a worldwide laboratory diagnostics market of USD 110.85 billion in 2025 with hospital laboratories representing 49.3% of end-user share, but this covers the broader laboratory diagnostics market and cannot be attributed to this niche without an unsupported allocation assumption. Sources [1], [6], [9] and [10] give differing clinical diagnostics totals (USD 92.37bn, USD 115.4bn, USD 86.5bn and USD 81.74bn for 2025 respectively), indicating definitional variance rather than a segment-level figure.

Alongside it in Clinical laboratories

// Sell into Routine core-lab testing

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.